Mounjaro vs Zepbound: Same Drug, Different Price

Mounjaro and Zepbound are the same molecule — tirzepatide — made by the same manufacturer, Eli Lilly. That surprises a lot of people who assume two different brand names mean two different drugs. They don't. What's actually different is the indication each brand is FDA-approved to treat, and that difference drives real gaps in price and coverage.

Same molecule, different indication

Per Mounjaro's current FDA label, tirzepatide under that brand name is indicated "as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus"¹ — it is a diabetes drug, full stop, at least as far as its approved label goes. Zepbound, the identical molecule at the same dose range, is indicated for chronic weight management and, more recently, for moderate-to-severe obstructive sleep apnea in adults with obesity² — see GLP-1 and sleep apnea: the SURMOUNT-OSA trial evidence for that trial. Lilly ran separate pivotal trial programs to earn each label: the SURPASS trials for diabetes behind Mounjaro, and SURMOUNT-1 for obesity behind Zepbound³. A prescriber can't simply write "Mounjaro" for a weight-loss-only patient and expect insurance to treat it the same as Zepbound — the indication on the label is what a payer checks against your diagnosis.

Why that split exists at all

Splitting one molecule into two brands by indication isn't unique to tirzepatide — Novo Nordisk does the same thing with semaglutide (Ozempic for diabetes, Wegovy for obesity), and we cover that pattern along with the interaction and dosing details both brands share in GLP-1 drug interactions: what to tell your prescriber. The commercial logic is straightforward: insurers, PBMs, and formularies price and cover diabetes drugs and weight-loss drugs very differently, even when the drug in the syringe is identical, so a manufacturer that wants broad diabetes coverage and a separate obesity-specific launch benefits from keeping the brands distinct.

The self-pay prices don't match either

Here's where the "same drug" framing gets genuinely useful for a cost-conscious shopper. As of this writing, Lilly's own direct-to-consumer self-pay program prices Zepbound starting at $299 per month for the lowest 2.5 mg dose, climbing to $699 for the higher maintenance doses (with a promotional $449 rate available on higher doses under certain refill conditions)⁴. Mounjaro's self-pay price through the same LillyDirect program is a flat $499 per month across every dose strength, 2.5 mg through 15 mg⁵. That means the identical molecule, from the identical manufacturer, through the identical direct-pay channel, can cost you less labeled as Zepbound at a low dose than labeled as Mounjaro at any dose — purely because of which indication you're being treated under.

If you have commercial insurance instead

If you're paying through commercial insurance rather than cash, the math flips again. Mounjaro's own manufacturer savings program advertises a copay as low as $25 for up to a three-month supply for eligible, commercially insured patients with Mounjaro coverage⁵ — a very different number than either self-pay price above, and one that only applies if your plan covers Mounjaro specifically for a diabetes diagnosis. We cover the broader pattern of savings-card eligibility gaps — who actually qualifies and who doesn't — in do GLP-1 savings cards actually lower the price?, including why Medicare and Medicaid patients are typically excluded from either brand's manufacturer card.

What this means if a provider offers you "the same drug, cheaper"

If a telehealth program tells you Mounjaro and Zepbound are interchangeable and offers to prescribe whichever is cheaper that week, be skeptical of anyone glossing over the indication requirement — a legitimate prescriber writes the brand that matches your diagnosis, not the one with the better price that day. That's a different question from compounded tirzepatide, which sidesteps the brand question entirely; see compounded vs brand-name GLP-1: which actually saves you money for that comparison, and if you have Medicare, the new bridge program changes brand-name affordability again — see the Medicare GLP-1 Bridge Program: what it actually covers in 2026.

Comparing the actual numbers

Because list and self-pay prices shift, always check the current rate rather than trusting a number you saw months ago. Compare tirzepatide pricing across verified cash-pay and compounded programs on our tirzepatide price board, and see how we score prescriber transparency about brand and indication in our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.